Aurobindo Pharma Ltd has informed the Exchange that the Board of Directors of the Company at its meeting held on November 12, 2009 has inter-alia considered and approved the following: 1) The draft Scheme of Amalgamation for the merger of Trident Life Sciences Limited being wholly owned subsidiary of the Company, with itself. Upon the Scheme becoming effective, all the assets and liabilities of Trident shall be transferred to Aurobindo. Aurobindo shall not issue any shares or other consideration as Trident is 100% subsidiary of Aurobindo. The Scheme is subject to requisite consent, approval of the requisite majority of the shareholders of the companies, the Honble High Court of Judicature at Hyderabad, Stock Exchanges, the permission or approval of any other statutory or regulatory authorities, which by law may be necessary for the implementation of the Scheme. 2) To convene the Annual General Meeting of the Company on December 23, 2009. 3) The Register of Members and Share Transfer Books of the Company will be closed from December 18, 2009 to December 23, 2009 (both days inclusive) for the purpose of Annual General Meeting and for payment of dividend for the year 2008-09.